EPO906 Therapy in Patients With Advanced Kidney Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will examine whether the investigational drug EPO906, given by intravenous
infusion (IV directly into the vein), is effective in shrinking tumors and preventing the
growth of cells that cause kidney cancer.